Cargando…

Potential and safety tests of egg drop syndrome candidate vaccine from Medan isolate, Indonesia

AIM: The study was aimed to prepare and examine the potential and safety concerns of egg drop syndrome (EDS) vaccine candidate seed. The potential and safety trials of EDS Medan isolate vaccine need to be done before commercial scale of EDS vaccines are made. MATERIALS AND METHODS: The safety test o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kencana, Gusti Ayu Yuniati, Suartha, Nyoman, Kardena, I Made, Dewi, Gusti Ayu Mayani Kristina, Nurhandayani, Arini, Syamsidar, Agustina, Kadek Karang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Veterinary World 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303488/
https://www.ncbi.nlm.nih.gov/pubmed/30587901
http://dx.doi.org/10.14202/vetworld.2018.1637-1640
Descripción
Sumario:AIM: The study was aimed to prepare and examine the potential and safety concerns of egg drop syndrome (EDS) vaccine candidate seed. The potential and safety trials of EDS Medan isolate vaccine need to be done before commercial scale of EDS vaccines are made. MATERIALS AND METHODS: The safety test of EDS candidate vaccine was tested on 4-week-old specified pathogen-free chickens in an experimentally isolated enclosure. RESULTS: The result of the safety test obtained 2(7.3) hemagglutination inhibition (HI) unit of geometric mean titer antibody post-vaccination. However, the potency test of the EDS candidate vaccine was conducted on 17-week-old laying hens. Test results of the EDS potency vaccine in layer obtained antibody titer increased in every week of blood taking with average titer of antibody: Before vaccinated was 2(2.9) HI unit, 1 week after vaccination was 2(3.7) HI unit, 2 weeks post-vaccination was 2(5) HI unit, and 3 weeks after vaccination was 2(7.3) HI units. In contrast, decreasing trend was observed in control group (unvaccinated chicken). CONCLUSION: Serologically, the seed vaccine of EDS virus isolates from Medan was able to produce protective antibody titers starting in the 2(nd) and 3(rd) weeks post-vaccination.